HUMA:NASDAQ, Humacyte, Inc.

Why HUMA stock rose on November 6

Humacyte, Inc. rose 13.3% on Friday, November 6, 2026, on 5,149,060 shares. Headlines around the move:

Nov 6: RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates
Nov 5: Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

HUMA stock overview

Humacyte, Inc. (HUMA:NASDAQ) closed at $0.448 on November 6, 2026, up 13.32% on the day. The stock trades 70.6% below its 52-week high of $1.53 and 33.0% above its 52-week low of $0.337. Over the past year, it lost 66.8%. Humacyte, Inc. is part of the Health Care sector.

Key figures

Price: $0.448
Day change: +13.32%
Volume: 5,149,060
Average volume: 6,643,910
Market cap: 124M+
52-week range: $0.337 – $1.53
50-day average: $0.504
200-day average: $0.794

Price action over the past year

In 252 trading sessions since November 6, 2025, HUMA closed higher on 112 days (44%). Its best day was February 9, 2026 (+30.06%) and its worst was March 19, 2026 (-19.43%). The stock moved 10% or more in a single session 29 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

Nov 2, 2026: News catalyst: Investor Update (News Catalysts scanner)
Oct 29, 2026: Spiked to $0.510 on 3M+ shares (Spikes scanner)
Aug 13, 2026: Dropped 17.3% in a single session (Dips & Crashes scanner)

HUMA news

About Humacyte, Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.

Similar stocks

Find more stocks like HUMA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.